Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.95 -3.77% 24.25 24.00 24.50 25.25 24.25 25.25 2,213,040 14:00:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.3 -5.6 -3.4 - 162

Open Orphan Share Discussion Threads

Showing 9976 to 9999 of 11950 messages
Chat Pages: Latest  406  405  404  403  402  401  400  399  398  397  396  395  Older
DateSubjectAuthorDiscuss
26/11/2020
10:52
Pogue, I'll ask him to confirm at the next investor presentation on the 9th.
gregb
26/11/2020
10:49
GregB so we are off and running on CV19 trials, they earn more money than the normal ones so nice finish to the year, I thought HM Gov had the first 3 in Jan.
pogue
26/11/2020
10:44
Yes Pouge, he said December.OO had a mention in this article back in August.https://www.biospace.com/article/biotech-startup-codagenix-plans-human-trials-for-covid-19-vaccine/
gregb
26/11/2020
10:44
Oh he's funny. Funniest thing I've heard in a longtime. Is that all proven cathal? No, it's a guess. Really, I think he should have catchpole answering pharma questions, and c answering the business questions.
pierre oreilly
26/11/2020
10:39
WRT the CEO, A lot of companies in this space are populated by directors that have a PHD background and know their science, but businessmen they aint. CF is, the company is run by relevant science background staff, he's the business brain converting that know how into revenue.
owenski
26/11/2020
10:34
m5, He has a very impressive salesman’s patter, that’s for sure
judijudi
26/11/2020
10:33
Codagenix phase 1 CV19 vaccine being tested by ORPH in December according to IG interview on above presentation, circa 4 mins in, we must have a challenge study model approved? Am I hearing that wrong?
pogue
26/11/2020
10:29
Jut listened to that all the way through, as you say very interesting. CF is certainly positive about the future in general, not just ORPH, and see's a lot of opportunities. Very bright and switched on bloke CF. He does have the effect on you wanting to buy more shares everytime he talks. As someone that knew nothing about the Industry he certainly has come a bloody long way and sees all the opportunities that maybe others just don't see. Massive asset for us.
m5
26/11/2020
10:19
Yes, thanks toyin, very interesting.
realcooltrader
26/11/2020
10:01
Cheers toyin.
m5
26/11/2020
09:49
https://youtu.be/8rm04FSyyFo
toyin
26/11/2020
09:49
Hopefully that November update brings some clarity for some institutional investors on the money being generated.
uapatel
26/11/2020
09:46
I agree we have a steady buyer that does not want to push the price up. I wonder why they are buying now. Do we have some news due anytime? :-)
m5
26/11/2020
09:38
I agree that someone is quietly buying on a daily basis so as not to raise the price as the shares are very liquid at the moment
malcolmmm
26/11/2020
09:33
😂🤣👏👏
judijudi
26/11/2020
09:31
Judi, it's "pin bars" not "behind bars”! 😉
toyin
26/11/2020
09:29
😃😃
judijudi
26/11/2020
09:27
Hi judujudi, 'Parkhurst' ? That's a bit unPC, surely (Shirley) ? What about 'Holloway' ;-> ? ATB
extrader
26/11/2020
09:14
Where Parkhurst? 😃
judijudi
26/11/2020
09:09
We have break out.
bramble13
26/11/2020
08:52
Shares Spotlight Article – ORPH hxxps://issuu.com/shares-magazine/docs/spotlight_shares_2611120
trader_3
26/11/2020
08:23
Supernumerary, cruel ;-)
warranty
26/11/2020
08:17
The Lancet Article – 30/10/2020 "The study will take place in the high-level isolation unit of the Royal Free Hospital, London, UK." The Human Challenge Consortium consists of UK Government representatives and experts from the National Health Service (NHS), academia, and the private sector. The group has come together to explore the feasibility and ethics of human challenge trials that could potentially accelerate the development of vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The first study phase, which could begin in January, 2020 ( should read 2021 !!!! ), aims to discover the smallest amount of virus it takes to cause the infection in up to 90 healthy young people, aged between 18 and 30 years, who are at the lowest risk of harm from COVID-19. The study will take place in the high-level isolation unit of the Royal Free Hospital, London, UK. DOI:hTTps://doi.org/10.1016/S2213-2600(20)30518-X
bobsworth
26/11/2020
07:57
The vaccine news is unraveling due to their cutting corners in testing what a surprise... hTTps://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html ...But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine’s apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results....
pogue
Chat Pages: Latest  406  405  404  403  402  401  400  399  398  397  396  395  Older
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210119 06:40:36